Stay updated on Sotatercept in PAH High-Risk Mortality Clinical Trial
Sign up to get notified when there's something new on the Sotatercept in PAH High-Risk Mortality Clinical Trial page.
Latest updates to the Sotatercept in PAH High-Risk Mortality Clinical Trial page
- Check5 days agoChange DetectedNo substantive content changes detected between the screenshots; study details and endpoints appear unchanged.SummaryDifference0.1%
- Check12 days agoChange DetectedRevision: v3.5.0 added, replacing the previous Revision: v3.4.3 on the page.SummaryDifference0.1%
- Check19 days agoChange DetectedResults data and related outcomes were added to the study record, including updates to primary and secondary endpoints. Study completion and primary completion dates were revised.SummaryDifference0.1%
- Check26 days agoChange DetectedExpanded the study eligibility to include idiopathic, heritable, drug/toxin-induced, CTD-associated PAH, and post-shunt correction cases, with more detailed baseline criteria and endpoints extending up to ~31 months. Removed the prior requirement of REVEAL Lite 2.0 score ≥9 and the mandate for maximum tolerated background PAH therapy, replacing it with broader inclusion and longer follow-up.SummaryDifference0.6%
- Check33 days agoChange DetectedAdded a dedicated Results section with the NEJM publication citation and updated study dates.SummaryDifference0.1%
- Check47 days agoChange DetectedRevision v3.4.2 was added and v3.4.1 was removed, a minor update to the page's versioning information; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
Stay in the know with updates to Sotatercept in PAH High-Risk Mortality Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sotatercept in PAH High-Risk Mortality Clinical Trial page.